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Bulleted statements (max 70 words per question)
a. What’s already known about this topic?
 Many long-term sequelae have been identified with cutaneous and ocular 
problems being amongst the most common
 A search of existing literature has identified a lack of research relating to the 
psychological impact on patients
b. What does this study add?
 SJS and TEN have long lasting psychosocial implications for the lives of those 
affected  and their significant others
 Health care practitioners’ (HCP) lack of information around the disorder 
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 Following discharge from the hospital, individuals expressed fear of taking 
medication and in attending their doctor, frequently leading them to engage in 
avoidance behaviours
 Patients were distressed with symptoms aligned to PTSD 
Abstract 
Clinical scenario A 65 year-old male presented with a 12 hour history of deteriorating rash. Two weeks 
previously, he had completed a course of neo-adjuvant chemotherapy for ductal carcinoma of the breast. 
On examination, there were bullae, widespread atypical targetoid lesions and 15% epidermal detachment. 
There was no mucosal involvement on presentation but, subsequently, it did evolve. Skin biopsy showed 
sub-epidermal blistering with epidermal necrosis. This confirmed our clinical diagnosis of overlap SJS-
TEN. On transfer to ICU, he was anxious and fearful. 
What are the psychological impacts of SJS/TEN on this man’s life?
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Objectives To conduct a critically appraised topic (CAT) to (1) analyse existing research related to the 
psychological impact of SJS and TEN and (2) apply the results to the clinical scenario. 
Methods Seven electronic databases were searched for publications focusing on the psychological impact 
of SJS TEN on adults over 18 years of age. 
Results Six studies met inclusion criteria. Health care practitioners’ (HCPs) lack of information around 
the disorder was highlighted. Patients experienced undue stress and fear. Some patients had symptoms 
aligned to post-traumatic stress disorder (PTSD), anxiety and depression. 
Discussion and recommendation for clinical case The evidence suggests that SJS and TEN impact 
psychologically on patients’ lives. Education of HCPs, to address their lack of awareness and information 
on SJS/TEN, should facilitate their capacity to provide information and support to patients, thereby 
reducing patient anxiety. On discharge, a follow up appointment with relevant HCPs to reduce the 
possibility of PTSD occurring should be considered.
Clinical scenario
A 65 year-old male presented as being acutely unwell with a 12 hour history of deteriorating rash. In the 
preceding two weeks, he had completed a course of neo-adjuvant chemotherapy for locally advanced 
invasive HER2 positive ductal carcinoma of the left breast. His medications included his chemotherapy 
agents viz. docetaxel, carboplatin and trastuzumab as well as intermittent dexametasone and 
domperidone.  On examination, there were bullae, widespread atypical targetoid lesions and 15% 
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evolve. Skin biopsy showed sub-epidermal blistering with epidermal necrosis. This confirmed our clinical 
diagnosis of overlap SJS-TEN. His SCORTEN (SCORe of Toxic Epidermal Necrosis) was four; with a 
projected mortality risk of 58%. On transfer to ICU, he was anxious and fearful.
What are the psychological impacts of SJS/TEN on this man’s life? 
Background
SJS and TEN are severe immune mediated mucocutaneous reactions, usually occurring as a result of 
medications.1 Many medications have been identified as causing the conditions some of which include 
allopurinol,2-4 sulphonamide antibiotics,3 anticonvulsant agents,4 oxicam, nonsteroidal anti-inflammatory 
drugs,3 chlormezanone,4 corticosteriods4 and nevirapine.3 Some ‘over-the-counter’ medications, such as 
acetaminophen, metamizole and ibuprofen, have also been linked to the conditions.2, 5, 6 However, 
Roujeau et al.7 highlight that the link between medications, such as acetaminophen, ibuprofen and 
secretolytics in causing SJS and TEN, may be as a result of protopathic bias. These conditions can be 
linked to infections such as HIV,8 herpes virus9 and mycoplasma pneumonia.10 A rare genetic 
predisposition (the genotype HLA-B*1502), which only occurs in persons of Chinese and Southeast-
Asian descent, is linked to causing the conditions where the genotype reacts with an environmental 
trigger viz. the absorption of carbamazepine.11 SJS and TEN are characterised, in the acute phase, by a 
febrile illness followed by cutaneous erythema with blister formation, skin and mucous membrane 
necrosis and detachment.12 The individual becomes critically ill within a short period of time and is 
treated as a medical emergency. The United Kingdom guidelines and French national care protocols, for 
the management of SJS and TEN, have noted that, if patients are not referred to a specialist area such as 
an Intensive Care Unit (ICU) or Burns Centre, the mortality outcome for the patient may be affected.1, 13 
SJS and TEN are on the same disease continuum.14 A severity of illness score viz. SCORTEN, which is 
calculated on days one and three, is a measure for determining the seriousness of the conditions.15 In SJS, 
a body surface area (BSA) of < 10% is affected; in the case of TEN ≥30% of the body surface is affected, 
whilst in-between is referred to as SJS/TEN overlap.16 Sekula et al.17 reported mortality rates of 23% and 
34% at six weeks and one year, respectively. 
The literature indicates that these conditions are rare in the general population viz. 1-2 per million per 
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cases per million person-years between 1995 and 2013.20 The study has noted that the incidence rate has 
been higher in patients aged under 10 years and 80 years or older. An increased susceptibility to SJS, in 
patients over 80 years, may be partly explained by polypharmacy within this age cohort.21 Difficulties in 
differentiating between erythema multiforme majus and SJS in these age groups may account for the 
higher incidence rates.22, 23 
Notwithstanding the rarity of the conditions outlined above, they have devastating outcomes for those 
affected. Many long-term sequelae have been identified, with cutaneous and ocular problems being 
amongst the most common;24 respiratory and gastrointestinal tracts may also be affected.25 At the onset, 
the focus of care is on preservation and maintenance of life. Whilst the British Association of 
Dermatologists (BAD) guidelines provide comprehensive details on the medical care and management of 
adult patients with SJS and TEN, authors have recommended further research into what constitutes 
optimal supportive care.1 According to Nogueira et al.,26 the conditions have significant psychological 
effects on the patients, causing them distress and anxiety. The French national diagnosis and care 
protocol for SJS and TEN refer to the importance of managing pain and psychological distress.13 
However, a search of existing literature has identified a dearth of research relating to the psychological 
impact of SJS and TEN on patients. According to Lee et al.,25 the long-term psychiatric and psychosocial 
sequelae of SJS and TEN remain unclear. 
The objective of this CAT is (1) to critically appraise existing research related to the psychological impact 
of SJS and TEN and (2) apply the results to the patient scenario. 
Methods
A CAT was completed based on the four main steps outlined by Callander et al.27
1. Formation of a focused question: 
The original question arose from clinical practice. Using the Population, Exposure, Outcome/Theme 
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(P) Adults over 18 years of age presenting with SJS or TEN
(E) Adverse reaction diagnosed as SJS or TEN 
(O) Psychological impact such as emotional upset/trauma, post-traumatic stress, anxiety, or other impact 
on individuals’ well-being and self-concept (Table S1; see Supporting Information).
2. Search for the best available evidence: 
Following the PRISMA guidelines,30 a systematic search was conducted sourcing and synthesising 
empirical evidence which used qualitative and/or quantitative research.29 The protocol for this review has 
been registered with the International Prospective Register of Systematic Reviews (PROSPERO) 
(CRD42018111369).31 
The CAT used the integrative review methodological process outlined by Whittemore and Knafl.29 This 
method facilitated the concurrent synthesis of qualitative and quantitative empirical evidence, which was 
necessary to answer our clinical question. Qualitative and quantitative empirical studies were included, 
and unpublished research theses and dissertations. 
We searched seven electronic international databases for publications and identified additional records 
through other sources, dating from January 2008 to December 2018 (Fig. 1). The search strategy was 
developed through consensus across the review team. Two information specialists (Librarians) (ID & 
LD) were on the review team and led on the search process. We carried out a preliminary search on 
Medline to determine the sensitivity and accuracy of selected search terms. The search terms included 
synonyms and Medical Sub-Headings (MeSH) describing SJS and TEN and psychological impact. We 
exported all records to EndNote and removed duplicates and studies outside of the date range. 
Fig 1.
Adhering to the inclusion and exclusion criteria, five authors (PO’R; CK; PM; ID; SR) screened the titles 
and abstracts (n=937) with four working in pairs and one reviewer (CK) acting as arbitrator, if required. 
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process viz. full text review (n=33). Two reviewers screened full text articles and a meeting was held to 
agree on the rationale for exclusion of studies. Six studies, which met the review inclusion criteria, were 
included (Table 1). Two reviewers (PO’R & SR) were involved in the data extraction of the final included 
studies. 
Table 1
3. Critical appraisal of the evidence: 
The six studies were critically appraised and screened using the Critical Appraisal Skills Programme 
(CASP).32 Two of the studies were qualitative and four were quantitative, two of which included a 
Doctoral thesis and a Masters thesis. CASP Qualitative Checklist and CASP Cohort Study Checklist were 
used respectively. Each paper was assigned a score; 0-20 for qualitative papers and 0-24 for the cohort 
study papers (Table 1) whereby answers ‘yes’=2, ‘can’t tell=1 and ‘no’=0.  Of the six studies, the CASP 
scores were as follows; 16 (n=1), 19 (n=1) and 20 (n=3) and one had a score of 24. 
4. Interpreting and applying the results: 
Data extraction was performed on the findings and results sections of the included studies. The original 
studies were re-read and compared with the data extract files for verification purposes and to identify any 
extraction errors. Data were then analysed, inductively using the steps outlined by Whittemore and 
Knafl29 viz. data reduction, categorisation, data comparison, conclusion drawing (thematic development). 
To strengthen the data analysis process, the data were interpreted using Braun and Clarke33 thematic 
framework analysis. Key words and statements were highlighted and formed initial codes, which were 
both descriptive, and interpretive.33 To establish a broader level of meaning, codes were clustered 
together to form potential themes, thus ensuring that they were relevant in answering the review 
question.33 Cross comparisons were made across themes to ensure consistency and rule out any 
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At the first stage of screening, 33 full text articles were assessed for eligibility and 27 full text studies were 
excluded with reasons (Fig. 1). Six studies were included in the CAT. The included studies were; 
qualitative34, 35 (n=2) and quantitative36-39 (n= 4) (Table 1). Two of the studies were from the UK,34, 35 two 
were from France36, 37, one was from Canada38 and one was from South Africa.39 Following analysis, two 
overarching themes were identified viz. 1) Impact of diagnosis for now and the future and 2) Living with 
the psychosocial impact. In each of these, two further subthemes were developed (Table 2). Quotations 
from the qualitative papers are presented in Table 2. 
Table 2
Theme 1: Impact of diagnosis for now and the future
HCPs’ lack of information regarding SJS and TEN appeared to have caused stress and anger on those 
affected. Engaging in avoidance behaviour has been identified as one of the ways that individuals appear 
to cope with the incumbent stress from SJS or TEN.
Sub-theme 1: Health Care Practitioners not Knowing - The Distress on Patients
Patients described feeling distressed when they initially had symptoms of SJS or TEN and presented to 
their doctor/hospital. They often did not know what to expect in the ‘here and now’ and into the future, 
due in part to failures in diagnosing the condition. They eventually found out that they had this 
devastating disease and, whilst it would have a significant impact on their lives, the degree of information 
that they received from HCPs was minimal, leading to feelings of anger, confusion and a lack of trust in 
HCPs.34, 35 They also expressed anger and regret that they were not listened to by the doctor, especially 
when they were providing the doctors with information that may have helped in the prevention of SJS or 
TEN and/or its diagnosis.34, 35
Sub-theme 2: Minimising the risks 
Patients learned to deal with the stress and distress of being diagnosed with SJS or TEN in different ways. 
In the case of the observed data, coping with the condition frequently led to individuals, not only 
avoiding medications that may have given rise to SJS or TEN, but also in being suspicious of all 
medications. Consequently, the impact of the diagnosis led to long-term avoidance behaviour.34, 35 
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taking medications. In the Dodiuk-Gad et al.38 study with 17 participants, the questionnaire ‘Impact of 
Events Scale-Revised’40 was used to establish evidence of PTSD. One of the factors within the scale was 
avoidance and 47% of participants (n=8) were above the cut off score. One patient expressed that they 
not only had a fear of medication but also a fear of attending the doctor.34
Theme 2: Living with the psychosocial impact 
Individuals who experience SJS or TEN refer to it as being a traumatic event in their lives. The evidence 
suggests that the conditions have long lasting impact on the lives of those affected and their significant 
others. 
Sub-theme 1: Living with the distress 
Patients, who experienced SJS or TEN, used language aligned to that of experiencing a traumatic event. 
As with research from those who have suffered PTSD, patients articulated that they sometimes 
experienced depression and flashbacks, constantly living with the fear that it may happen again.34, 35
They were physically stripped of their skin, which was an external manifestation of what was happening 
to them emotionally. One man described how he was still trying to cope with the trauma of the illness. 
He described being scarred in his mind as well as in his body. 34 Trauma was also a key finding of the 
papers which quantitatively assessed the impact of SJS or TEN. In the Dodiuk-Gad et al.38 study, 71% 
(n=12) had scores indicating clinically significant psychological distress; 65% of participants (n=11) had 
symptoms of post-traumatic stress. In addition, 29% of participants (n=5) had total scores, consistent 
with ‘clinical signs of possible PTSD’.38 While many patients experienced psychological distress, anxiety 
or depression, only a small minority were assessed by a mental health professional during the period 
following diagnosis. Similarly, Raspaud36 reported that following discharge with an initial diagnosis of 
TEN, 12 patients from a sample of 15, presented with anxiety, depression, irritability, insomnia and 
nightmares. Zitha39 found that of 26 patients diagnosed with SJS, TEN or SJS-TEN overlap ((n=16), 
(n=7) (n=3), respectively), 11 had anxiety and 13 were depressed at 6 months, following initial diagnosis. 
Using the Hospital Anxiety Depression Scale (HADS)41, 42% of patients (n=11) presented with a 
comorbidity of anxiety and depression [median HADS score 15.3; IQR 0.75-19.25]. The Hefez et al37 
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Sub-theme 2 – Impact on Self and Others
The diagnosis of SJS or TEN not only affected all aspects of the patient’s life but also their relationship 
with significant others. Living with SJS or TEN caused them to fear for the future, particularly in relation 
to protecting their children from the condition. As highlighted in Theme 1, patients were frequently left 
with many unanswered questions by HCPs; this posed many challenges. The future could feel uncertain 
and unsafe; difficulty in coping with this uncertainty was particularly challenging.35 
A sense of loss and sadness was evident in some patients’ descriptions, with one man reporting how the 
illness had a long-term impact on his relationship with his wife due to him not being able to enjoy sex.35 
Similarly, the misdiagnosis of SJS by a doctor led to stress and stigma, whereby a patient described being 
tested for every known sexually transmitted disease which affected her personal relationship.35 
There is evidence from the data that SJS and TEN affected the individual’s self-image and how others 
viewed them.35 They were ‘stripped bare’ of their self-image and of their friends. One patient described 
the look of disgust on the face of those who visited him and described himself as a ‘monster’.35
SJS and TEN affected all aspects of quality of life. Using the Dermatology Life Quality Index42 Zitha39 
reported that at 6 months, following initial diagnosis, the quality of life of 53% of patients (n=14) 
diagnosed with SJS or TEN or SJS-TEN overlap was moderately to extremely affected. Raspaud36 
referred to the medical file of one patient where it was noted that there was a repercussion on the 
patient’s socio-professional and personal life, a restriction on their daily activity and an aesthetic 
discomfort. Dodiuk-Gad et al.38 found ‘major long-term, overlooked and treatable psychological 
complications and a decreased Health Related Quality of Life (HRQOL) among survivors, following a 
mean 51.6 +/_4.7 months (median 9, range 1–228) after SJS or TEN’. They also found that only 29% of 
participants (n=5) were employed following diagnosis. This was a common theme where Raspaud36 also 
found that one third of participants (n=7) were in receipt of an allowance for adults with disabilities or 
disability compensation benefit. Patients highlighted that they had lost their job or had difficulty in getting 
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Empirical literature, exploring SJS and TEN, is predominately focused on the concomitant care, 
management and physical sequelae related to the conditions. There is a paucity of studies focused solely 
on the psychological consequences and on the impact of the conditions on patients’ lives. Our CAT has 
identified six studies exploring the psychological impact of SJS and TEN and has revealed limited 
evidence. This lack of research may be attributed to the rarity of the disorder.  
The available evidence suggests that SJS and TEN have a psychological impact which may have lasting 
implications on the quality of life of those affected and their significant others. Some patients were left 
feeling distressed with symptoms aligned to PTSD, anxiety and depression. Patients revealed that they 
were confused and unaware of how it was going to affect their lives from the time of diagnosis onwards, 
which could also negatively impact their relationships with significant others. Patient accounts identified a 
lack of knowledge on the part of the HCPs around the disorder. Consequently, patients were poorly 
informed. Following discharge from hospital, individuals expressed fear around taking medication and in 
attending their doctor and, subsequently, engaged in avoidance behaviour. 
Many experts in the area have highlighted the importance of managing, researching and preventing the 
psychological sequelae in patients with SJS and TEN.13, 16, 25, 43 Although some evidence exists, more 
clarity and research are required regarding the impacts on individuals’ lives.25 Eckert et al.44, in a meeting 
abstract, have documented the importance of HCPs putting strategies (not identified) in place to prevent 
the possible psychological sequelae such as PTSD in patients with SJS and TEN. 
Patients with SJS or TEN are considered a similar cohort to burns patients in terms of experiencing a 
traumatic event. Identifying how the psychological care is managed with burns patients may be beneficial 
in the development of psychological support strategies for patients with SJS and TEN. Evidence has 
highlighted that there is a very close link between PTSD and the use of avoidance coping behaviours in 
burns patients and traumatised patients, which can affect recovery from the traumatic event.45-47 
Renneberg et al.48 have proposed the implementation of routine screening of psychological distress and 
the ability to cope in burns patients. In addition, hypnosis, distraction techniques and relaxation therapy 
are some supportive interventions used with such patients in managing pain and psychological concerns 
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Whilst the rarity of SJS and TEN poses research challenges,14 particularly in terms of participants, it is an 
opportunity to commence research dialogue on a global front, so as to address such anomalies. This 
approach has been adopted by the International Rare Diseases Research Consortium.51 
Clinical Message
We conclude there is limited evidence detailing how best to minimise the psychological impact of SJS and 
TEN on patients. More research is required to address how best psychological care should be 
incorporated into the patient’s supportive care plan. 
Our patient was cared for in the ICU by a multidisciplinary team, encompassing the expertise of the 
dermatological team and the ICU specialists. This provided reassurance to both the patient and their 
family. In light of the findings from our CAT we took the following actions which should be considered 
in reducing the psychological impact on patients presenting with SJS or TEN.   
 Patients have a right to information regarding their condition and the provision of it should allay 
some potential stresses. It is crucial to have meaningful patient involvement, from the onset, so as 
to ensure that their experiences inform decision-making and care pathways. 
 HCPs need to be aware of SJS and TEN to assist in early patient diagnosis. Lack of awareness 
and information from HCPs has caused stress and anxiety for patients. Using education and 
training to increase HCP awareness and knowledge concerning SJS and TEN should facilitate 
their capacity to provide information, support or referral opportunities to patients and family 
members, thereby reducing anxiety whilst increasing satisfaction with care. 
 The patient’s care environment needs to be as stress free and person centred as possible. 
 On discharge, a follow up appointment with the relevant HCP, such as a psychologist 
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Table 1 Characteristics of included studies
Author Year Country Aim/Purpose Type Study Participants Key Message CASP 
Butt et 
al.,34
2011 UK To explore the 
experiences and 
beliefs of patients 
who had SJS/TEN 









n=14 participants (n=8 
female/n=6 male) Age 
range 21-82 years. 
Direct quotes from 
interviews referenced in 
Table 2 as ‘patient n’. 
Life threatening ADRs such as SJS 
and TEN may continue to affect 
patients’ lives long after the event 
having an impact on their current 
lives physically and psychologically. 
Patients can lose trust in healthcare 





2012 UK To illuminate 
patient experiences 
of SJS and TEN by 
analysing 
unsolicited  internet 
narratives or 
postings of those 







n=139 posts from those 
with direct experience of 
SJS/TEN and n=69 by 
Patients and relatives with experience 
of SJS or TEN posted on support 
group websites to share their 
experiences, provide support to other 
sufferers and obtain advice from 
others with similar experiences. 
Findings indicted that patients and 
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personal experience 
of drug induced 
SJS and TEN.
relatives.
Direct quotes from posts 
referenced in Table 2 as 
‘internet description n’. 
about the ADR often long after the 
event.
Raspaud36 2014 France To describe the 
sequelae of SJS and 
TEN including 







n=21 participants (n=18 
female/n=3 male)
SJS and TEN can cause long term 
sequelae including cutaneous (70%), 
psychological (60%) and ocular 
(45%) complications. Psychological 
sequelae are an important part of SJS 





2018 France To assess the 
prevalence of 
PTSD and its risk 
factors in a 
population of 
adults with 






n=31 patients (n=19 
female/n=12 male)
Despite frequent prescription of 
hydroxyzine at the acute phase, 
almost one quarter (23%) of patients 
with SJS/TEN had PTSD at 6 
months. A systematic psychiatric 
evaluation should be offered regularly 
for at least 1 year after the acute 



























n=17 participants (n=11 
female/n=6 male) 
Survivors of SJS/TEN had major 
long-term, overlooked and treatable 
psychological complications and 
decreased  HRQOL following a 
mean 51.6 ± 74.7 months (median 9, 
range 1–228) after SJS/TEN. 
Psychological support during 
hospitalization, prior to discharge and 
throughout follow up should be 
offered to all patients. 
20/24




presence of anxiety 
and depression in 
patients with severe 
cutaneous adverse 
drug reactions 
(SCADR), as well 
as assess their 
Quantitative 
Study 
n=48 participants (n=35 
female/n=13 male) 
n=34 participants were 
diagnosed with SJS, TEN 
or SJS-TEN overlap.
There is a high prevalence of anxiety 
and depression among patients with 
SJS/TEN and the disease negatively 
affects quality of life. At 6 weeks post 
diagnosis 13/34 patients with 
SJS/TEN had both anxiety and 
depression while at 6 months 11/26 
were cases of comorbid anxiety and 
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quality of life at 
two time intervals, 
using validated 
scoring systems.
of life of 14/26 patients was 
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Table 2: Themes, subthemes and representative quotes from qualitative papers34, 35
Theme Subtheme Representative quotes
1. Impact of 
diagnosis for 
now and the 
future
1. Health Care 
Practitioners not 
knowing – the 
distress on 
patients
“Well, I'd never heard of it, and when the doctors themselves 
didn't know anything about it, it was all a bit scary ...” 
(Patient 1)34
"I definitely feel that the medical profession is not aware 
enough of Stevens-Johnson.” (Internet description 195)35
“I was amazed at the lack of knowledge on the part of the 
medical professionals. I clearly knew more about this disorder 
than anyone else I dealt with” (Internet description 67)35
"... the doctor diagnosed me with things like chicken pox, 
measles, and flea bites ..." (Internet description 136)35 
"... my mom looked frantically through a book of medical 
problems and came to Steven Johnsons Syndrome. It fit the 
description perfectly but when she asked the doctor if it could be 
that he said no, it's too rare ..." (Internet description 
136)35 
"I'm totally clueless about SJS though. Am I now a carrier? 
I'm aware of the fact it was due to an allergic reaction to the 
drugs prescribed to me. I think I was extremely lucky as it 
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anyone update me on what happens now with regards to SJS 
and me being a carrier? I'm aware I shouldn't use that 
medicine ever again” (Internet description 216)35
“Well I felt bitter that I should not have been given cefalexin, 
but it was on my notes it said I'm allergic to penicillin ... and 
there is a train of thought that cefalexin is closely related to 
penicillin, and she [the GP] shouldn't have given me that 
knowing my history, all my notes say no penicillin .... I feel she 
[the GP] should have looked it up on the Internet, she's got 
the means, she should have inquired rather than handing out 
willy-nilly ..."’ (Patient 4)34 
"But the only thing now is, it's made me so scared of taking 
pills.... I won't go to the doctors if I can help it now ... um, you 
know if you got infections or anything like that, I won't go, 
and if I had to go, was forced to go, he gives me tablets, I ask 
him ... I must be the worst person, the worst nightmare they've 
had! [smiles] ... I ask him, then I ask the chemist [laughs], 
then I think, I'm not taking them! Just in case, you know? 
It's frightening ..." (Patient 1)34
"I am still quite confused by this syndrome. Will it stay in her 
system forever? Since it is a syndrome, does it always come 
back and never go away? I don't know anymore and I am 
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2. Minimising the 
risks
‘I stopped taking any medication unnecessarily, like 
paracetamol, penicillin, Nurofen®, and ... Lockets® 
[medicated lozenges], because they're like medicated inside 
aren't they ... and, so I stopped taking all that kind of stuff... 
and I get really bad migraines as well, that will actually make 
me throw up, but I still don't take Nurofen®.... because of the 
chance ...’ (Patient 7)34
‘I think it's just made me aware of everything really ... um, if 
er, if new sweets have come on [to the market] or anything ... 
from different foods, you think, knowing that it's stupid! But it 
does ... you think about it!’ (Patient 1)34
"... in the meantime, we live one day at a time, suspicious of all 
meds, suspicious of all foods, and even suspicious of the air that 
James breathes ... why, why, why???" (Internet description 
92)35
2. Living with 
the psychosocial 
impact
1. Living with the 
distress
"Yes ... being depressed, yes, because as I said I get flashbacks, 
your memory goes but you remember certain things like when 
I'm having a shower or taking my top off or look in the mirror 
it all comes back again." (Patient 13)34
“I will never forget. I feel traumatized and sometimes I feel 
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“Yes because I'm scarred in my mind as well as scarred on my 
body ... I have  flashbacks to my illness ... the doctors were 
great and the hospital was great ... but what let me down was 
the aftercare because ok, I got home and had to go back for 
checkups, but I said what about my scars? And the doctor was 
great he said you're a big strong lad, you'll be able to cope, but 
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